Briciclib

Research use only, not for human use.

Briciclib is a small molecule that suppresses cyclin D1 accumulation in Y cells.

Briciclib is a small molecule that suppresses cyclin D1 accumulation in Y cells.(In Vitro):Briciclib has the potential in targeting eIF4E. Briciclib shows inhibitory activity against the proliferation of mantle cell leukemia (EKO-1 and MINO), breast (MCF7 and MDA-MB-231), gastric (AGS), and esophageal (OE19, OE33, and FLO-1) cancer cell lines with GI50s of 9.8-12.2 nM, and with no toxicity on normal endothelial cells. Briciclib dose-dependently reduces the expression of cyclin D1 and c-Myc in breast and MCL cancer cell lines within 8 hours.

Briciclib has the potential in targeting eIF4E. Briciclib shows inhibitory activity against the proliferation of mantle cell leukemia (EKO-1 and MINO), breast (MCF7 and MDA-MB-231), gastric (AGS), and esophageal (OE19, OE33, and FLO-1) cancer cell lines with GI50s of 9.8-12.2 nM, and with no toxicity on normal endothelial cells. Briciclib dose-dependently reduces the expression of cyclin D1 and c-Myc in breast and MCL cancer cell lines within 8 hours.

——

ON 014185

Cytoskeleton/Cell Adhesion Molecules

Microtubule/Tubulin

Cyclin D1

Cancer

——

865783-99-9

474.42

C19H23O10PS

>98% (HPLC)

DMSO : ≥ 31 mg/mL; 65.34 mM

c1(cc(c(c(c1)OC)/C=C/S(=O)(=O)Cc1ccc(c(c1)OP(=O)(O)O)OC)OC)OC

——

(-20℃)

With Ice Pack

≥ 2 years